Medical Abstract Title:
Comparative Study Of Hormone Replacement, Including Transdermal And Oral Bio-Identical Natural Hormones And Homeopathic Hormone Stimulation And Rejuvenation Using Salivary Testing As A Diagnostic Tool.
Theresa Dale, PhD, CCN, NP.
President, The Wellness Center for Research & Education, Inc.
Founder and Dean
California College of Natural Medicine
Homeopath, Researcher, Inventor, Medical Consultant, Clinical Nutritionist,
Traditional Naturopathic Doctor & Practitioner (CA)
To determine if homeopathy and specific homeopathic formulas could help women’s hormonal symptoms related to menopause, post menopause, post-partum depression and PMS and reactivate the HPA axis communication thus producing normal return of chronobiology and hormone levels and if so, to what degree would it be effective.
Homeopathy is a 200 year old proven and FDA approved method for curing disease. Individual ingredients in the formulas are listed as OTC in the Homeopathic Pharmacopia of the United States meaning that they are proven effective. The Homeopathic Pharmacopoeia of the United States (HPUS) is the official compendium for Homeopathic Drugs in the U.S.
Female patients were in the following phases of their life: cycling with PMS, premenopausal and postmenopausal, including women with partial or complete hysterectomies. 60% or more of the patients were using or had used some type of HRT in the last 3 year; DHEA or pregnenalone, herbal therapy, cortisone or other types of medication, birth control pills, or IUD’s which secrete birth control hormones. Approximately 40% of patients were not using or were not aware of exposure to or used HRT in thier lifetime.
METHODS: Using a 24-hour circadian salivary testing with specific testing times according to the Chinese Medicine Five Element Body Clock, thousands of saliva tests were submitted by patients/clients of health providers directly to independent CLIA licensed laboratories.
The factors used in the analysis of hormonal ratios on each individual test result included age, medical history of surgical procedures such as partial and/or complete hysterectomies, genetic information, diet, exercise (lifestyle), medication usage, including any type of hormone replacement usage (HRT and BHRT).
To reveal an accurate baseline test to those women using HRT and desiring to stop usage, salivary testing was administered after discontinuing HRT for 10 days before the specimens were collected. Testing was administered both in the follicular and the luteal cycle to determine efficacy of the homeopathic hormone rejuvenation formulas. For the first 5,000 tests, specimen collection occurred on the second day of the menstrual cycle or, in the case of very infrequent menstruation or menopause, testing was administered the second day of the month. The balance of the testing was performed according to the 19th day of cycle for menstruating women and the second day of
the month for menopausal women.
The following hormones were analyzed: 5 cortisol levels at specific times related to organ and meridian function, progesterone, free testosterone, three estrogens (estradiol, estriol, estrone), and DHEA levels.
Homeopathic hormone transdermal formulas (FDA registered) was administered according to initial test results for a period of three to six months according to health providers recommendations with repeated salivary testing to monitor results. A dietary regime was also suggested.
RESULTS: From 2000 to 2011, approximately 20,000 salivary tests were analyzed. The Women’s Health Initative’s study proved that HRT can cause serious health conditions such as cancer. The saliva testing analysis confirmed the abnormal hormonal levels and illness caused by HRT usage.
After using homeopathic (non-toxic) hormone rejuvenation for approximately three to six months or sooner, symptoms improved according to new case history, one repeated salivary test and communication with health provider and patient. Thereafter, repeated saliva testing results revealed even further progress in balancing hormone ratios and balancing cortisol levels.
Repeated testing indicated that 95% of patients had relief in the severity or the elimination of hormone related symptoms. Moreover, 90% of patients, whose initial salivary test results indicated a low DHEA level, resulted in an increase in DHEA within three months when formulae containing homeopathic remedies were administered during specific days of the monthly cycle.
CONCLUSIONS: Hormone replacement of any kind is dangerous and creates a toxic build-up of
hormones, even if monitored. After stopping HRT for 10 days before specimen collection, saliva
tests still revealed elevated and abnormal levels of HRT.
Adrenal cortisol stress can be the sole cause of hot flashes and other symptoms. Cortisol in humans is the principal glucocorticoid and it influences appetite and well-being, maintains blood sugar concentrations by promoting hepatic gluconeogenesis, and indirectly affects heart rate and pumping force by controlling synthesis of epinephrine in the adrenal medulla. Furthermore, Normal cortisol secretion is critical in the physiologic response to stress and illness.
Elevated hormone levels from hormone replacement (HRT or BHRT) can cause adrenal cortisol stress, liver toxicity, and abnormal hormonal ratios.
Through this study, Homeopathic formulas containing multiple remedies has shown the ability to reactivate and rejuvenate cellular communication to the HPA axis assisting in normal biological hormone production.
The hypothalamic-pituitary-adrenal axis (HPA or HTPA axis), also known as the limbichypothalamic-pituitary-adrenal axis (LHPA axis), is a complex set of direct influences and feedback interactions among the hypothalamus (a hollow, funnel-shaped part of the brain), the pituitary gland (a pea-shaped structure located below the hypothalamus), and the adrenal (or suprarenal) glands (small, conical organs on top of the kidneys). The interactions among these organs constitute the HPA axis, a major part of the neuroendocrine system that controls reactions to stress and
regulates many body processes, including digestion, the immune system, mood and emotions, sexuality, and energy storage and expenditure.
This research places hormone “replacement” of any kind at a unquestionable disadvantage.
1. Orth DN, Kovaks WJ, DeBold CR: The adrenal cortex. William’s Textbook of Endocrinology, 8th ed. Wilson JD, Foster DW, Eds. WB Saunders Co, Philadelphia, 1992, p 489
2. Meikle AW, Daynes RA, Araneo BA: Adrenal androgen secretion and biologic effects. Endocrinol Metab Clin North Am 20:381, 1991 [ 1831756]
3. Quinn SJ, Williams GH: Regulation of aldosterone secretion. Ann Rev Physiol 50:409, 1988
4. Orth DN: Corticotropin-releasing hormone in humans. Endocr Rev 13:164, 1992
5. Watabe T, Tanaka K, Kumagae M, et al: Role of endogenous arginine vasopressin in potentiating corticotropin-releasing hormone-stimulated corticotropin secretion in man. J Clin Endocrinol Metab 66:1132, 1988 [ 2836468]
6. Salata RA, Jarrett DB, Verbalis JG, et al: Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. J Clin Invest 81:766, 1988 [ 2830315]
7. Iranmanesh A, Lizarralde G, Short D, et al: Intensive venous sampling paradigms disclose high frequency adrenocorticotropin release episodes in normal men. J Clin Endocrinol Metab 71:1276, 1990
8. Dallman MF, Akana SF, Levin N, et al: Corticosteroids and the control of function in the hypothalamo-pituitary-adrenal (HPA) axis. Ann NY Acad Sci 746:22, 1994 [ 7825879]
9. Findling JW, Engeland WC, Raff H: The use of immunoradiometric assay for the measurement of ACTH in human plasma. Trends in Endocrinol Metab 1:283, 1990
10. Kaye TB, Crapo L: The Cushing syndrome: an update on diagnostic tests. Ann Intern Med 112:434, 1990
11. Kannan CR: Diseases of the adrenal cortex. DM 34:613, 1988
12. Seeler LR: Cushing’s syndrome. Cleve Clin J Med 55:329, 1988
13. Biller BMK, Alexander JM, Zervas NT, et al: Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing’s disease. J Clin Endocrinol Metab 75:1303, 1992
14. Odell WD: Ectopic ACTH secretion: a misnomer. Endocrinol Metab Clin North Am 20:371, 1991
15. Ulick S, Wang JZ, Blumenfeld JD, et al: Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 74:963, 1992 [ 1569172]
16. Williams GH: Guardian of the gate: receptors, enzymes, and mineralocorticoid function (editorial). JClin Endocrinol Metab 74:961, 1992
17. Belsky JL, Cuello B, Swanson LW, et al: Cushing’s syndrome due to ectopic production of corticotropin-releasing factor. J Clin Endocrinol Metab 60:496, 1985 [ 2982899]
18. King DR, Lack EE: Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases. Cancer 44:239, 1979 [ 455249]
19. Malchoff CD, MacGillivray D, Malchoff DM: Adrenocorticotropic hormone-independent adrenal hyperplasia. Endocrinologist 6:79, 1996
20. Hermus AR, Pieters GF, Smals AG, et al: Transition from pituitary-dependent to adrenal-dependent Cushing’s syndrome. N Engl J Med 318:966, 1988
21. Young WF Jr, Carney JA, Musa BU, et al: Familial Cushing’s syndrome due to primary pigmented nodular adrenocortical disease: reinvestigation 50 years later. N Engl J Med 321:1659, 1989
22. Reznik Y, Allali-Zerah V, Chayvialle JA, et al: Food-dependent Cushing’s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 327:981, 1992
23. Lacroix A, Bolte E, Tremblay J, et al: Gastric inhibitory polypeptide-dependent cortisol hypersecretion-a new cause of Cushing’s syndrome. N Engl J Med 327:974, 1992
24. Bertagna X: New causes of Cushing’s syndrome (editorial). N Engl J Med 327:1024, 1992
25. Kreisberg R: Half a loaf. N Engl J Med 330:1295, 1994
26. Findling JW: Clinical application of a new immunoradiometric assay for ACTH. Endocrinologist 2:360, 1992
27. Snow K: Biochemical evaluation of adrenal dysfunction: the laboratory perspective. Mayo Clin Proc 67:1055, 1992
28. Flack MR, Oldfield EH, Cutler GB Jr, et al: Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome. Ann Intern Med 116:211, 1992 29.
30. Zarate A, Kovaks K, Flores M, et al: ACTH and CRF-producing bron chial carcinoid associated with Cushing’s syndrome. Clin Endocrinol 24:523, 1986
31. Grossman AB, Howlett TA, Perry L, et al: CRF in the differential diagnosis of Cushing’s syndrome: a comparison with the dexamethasone suppression test. Clin Endocrinol 29:167, 1988
32. Nieman LK, Cutler GB Jr, Oldfield EH, et al: The ovine corticotropin-releasing hormone (CRH) stimulation test is superior to the human CRH stimulation test for the diagnosis of Cushing’s disease. J Clin Endocrinol Metab 69:165, 1989
33. Schulte HM, Allolio B, Gunther TK, et al: Bilateral and simultaneous sinus petrosus inferior catheterization in patients with Cushing’s syndrome: plasma-immunoreactive-ACTH-concentrations before and after administration of CRF. Horm Metab Res (suppl) 16:66, 1987
34. Loriaux DL, Nieman L: Corticotropin-releasing hormone testing in pituitary disease. Endocrinol Metab Clin North Am 20:363, 1991
35. Malchoff CD, Orth DN, Abboud C, et al: Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med 84:760, 1988
36. Gold PW, Loriaux DL, Roy A, et al: Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing’s disease. N Engl J Med 314:1329, 1986
39. Groote Veldman R, Meinders AE: On the mechanism of alcohol-induced pseudo-Cushing’s syndrome. Endocr Rev 17:262, 1996
40. Prevalence of 3-hydroxysteroid dehydrogenase–deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess American Journal of Obstetrics and Gynecology September 1999 • Volume 181 • Number 3
Carlos Moran, MD, MS, H. Downing Potter, BS, Rosario Reyna, BS, d, Larry R. Boots, PhD, Ricardo Azziz, MD, MPH.
41 1: J Nutr 2001 May;131(5):1621S-5S Human saliva as a diagnostic specimen. Hofman LF. Saliva Testing and Reference Laboratory, Inc., Seattle, WA 98104. PMID: 11340128 [PubMed – in process]
42 1: Endocr Res 2000 Nov;26(4):489-504 Fetal hypothalamic-pituitary adrenal (HPA) development and activation as a determinant of the timing of birth, and of postnatal disease. Challis J, Sloboda D, Matthews S, Holloway A, Alfaidy N, Howe D, Fraser M, Newnham J. Department of Physiology, University of Toronto, Ontario, Canada.2PMID: 11196419 [PubMed – indexed for MEDLINE]
43 Van Goozen SH, Weigant VM, Endert E, Helmond FA, Van de Poll NE. Psychoendocrinological assessment of the menstrual cycle: the relationship between hor-mones, sexuality, and mood. Arch Sex Behav 1997;26(4):359-382.
44 Lee KA, Shaver JF, Giblin EC, Woods NF. Sleep patterns related to menstrual cycle phase and premenstrual affective symptoms. Sleep 1990; 13(5):403-409.
45 Dye L, Blundell JE. Menstrual cycle and appetite control: implications for weight regu-lation. Hum Reprod 1997;12(6):1142-1151.
46 Redei E, Freeman EW. Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symp-toms. Psychoneuroendocrinol 1995; 20(30):259-267.
47 Berthonneu J, Tanguy G, Janssens Y, Guichard A, Boyer P, Zorn JR, Cedard L. Salivary oestradiol in spontaneous and stimulated menstrual cycles. Hum Rep 1989;4:625-28.
47 De Boever J, Kohen F, Bouve J, Leyseele D,Vandekerckhove D. Direct chemilumines-cence immunoassay of estradiol in saliva. Clin Chem 1990;36:2036-41.
48 Wong Y, Mao K, Panesar NS, Loong EP, Chang AM, Mi ZJ. Salivary estradiol and prog-esterone during the normal ovulatory menstru-al cycle in Chinese women. Eur J Obst Gynecol and Rep Biol 1990;34:129-35.
49 Vining R, McGinley R, and Symons R. Hormones in saliva: mode of entry and conse-quent implications for clinical interpretation. Clin Chem 1983;29:1752-56.
50 Bhagavan NV. Medical Biochemistry. Boston: Jones and Bartlett Publishers; 1992, 805-807.
51 Vuorento T, Lahti A, Hovatta O, and Huhtaniemi I. Daily measurements of salivary progesterone
reveal a high rate of anovulation in healthy students. Scan J Clin Lab Invest 1989;49:395-401.
52 Danutra V, Turkes A, Read G, Wilson D, Griffiths V, Jones R, Griffiths K. Progesterone concentrations in samples of saliva from ado-lescent girls living in Britain and Thailand, two countries where women are at widely differing risk of breast cancer. J Endocrin 1988; 121:375-81.
53 Finn M, Gosling J, Tallon D, Joyce L, Meehan F, Fottrell P. Follicular growth and corpus luteum function in women with unexplained infertility, monitored by ultrasonography and measurement of daily progesterone. Gynecol Endocrin 1989;3:297-308.
54 Vuorento T, Hovatta O, Kurunmaki H, Ratsula K, Huhtaneimi I. Measurements of salivary progesterone throughout the menstrual cycle in women suffering from unexplained infertility reveal high frequency of luteal phase defects. Fertil Steril 1990;54:211-16.
55 Vuorento T, and Huhtaniemi I. Daily measure-ments of salivary progesterone during men-strual cycle in adolescent girls. Fertil Steril 1992;58:685-90.
56 Wren B. Reproductive endocrinology. In: Hacker N and Moore J., editors. Essentials of obstetrics and gynecology. Philadelphia: W. B. Sanders Co., 1992.
57 Ronkainen H, et al. Physical exercise-induced changes and season-associated differences in the pituitary-ovarian function of runners and joggers. J Clin Endocrin Metab 1985;60:416.
58 Lipson S and Ellison P. Normative study of age variation in salivary progesterone profiles. J Biosoc Sci 1992;24:233-44.
59 Hamilton C, Wetzels L, Evers J, Hoogland H, Muijtjens A, de Haan J. Follicle growth curves and hormonal patterns in patients with luteinized unruptured follicle syndrome. Fertil Steril 1985;43:541-48.
60 van Zonneveld P, te Velde E, Koppeschaar H. Low luteal phase serum progesterone levels in regularly cycling women are predictive of sub-tle ovulating disorders. Gynecol Endocrin 1994;8:169-74.
61 Ayers J, Birenbuam DL, Menon KM. Luteal phase dysfunction in endometriosis: elevated progesterone levels in peripheral and ovarian veins during the follicular phase. Fertil Steril 1987;47:935-39.
62 Wingfield M, O’Herlihy C, Finn M, Tallon D, Fottrell P. Follicular and luteal phase salivary progesterone profiles in women with endometriosis and infertility. Gynecol Endocrin 1994;8:21-25.
63 Pirke KM, Schweiger U, Laessle R, Dickhaut B, Schweiger M, Waechtler M. Dieting influences the menstrual cycle: vegetarian versus nonvege-tarian diet. Fertil Steril 1986;46:1083.
64 Karmen B. Hormone replacement therapy: yes or no? Novato, CA: Nutrition Counter, Inc., 1993.
65 Wilson D, Turkes A, Jones R, Danutra V, Read G, Griffiths K. A comparison of menstrual cycle profiles of salivary progesterone in British and Thai adolescent girls. Eur J Cancer 1992; 28A:1162-
66 De Cree C, Lewin R, Ostyn M. The monitoring of the menstrual status of female athletes by salivary steroid determination and ultrasonog-raphy. Eur J App Physiol 1990;60:472-77.
67 Keizer H. Exercise- and training-induced men-strual cycle irregularities (AMI). Int J Sports Med 1986;8(suppl 3):137-74.
68 Keizer H, Poortman J, Bunnick G. Influence of physical exercise on sex steroid metabolism. J Appl Physiol 1980;48:765-69.
69 Wentz A. Cigarette smoking and fertility. Fertil Steril 1986;46:365.